Fund shareholders of BOLT BIOTHERAPEUTICS INC
ISIN US0977022039 · United States · LEI 254900W0P77PQ6B8OY50
- Fund shareholders
- 6
- Of which ETFs
- 0 6 other funds
- Value held
- 154.8K $
- Share of capital
- 1.6 % of 1.9M shares on Aug 4, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 17,060 | 89.6K $ | 0.00 % | 0.89 % | as of May 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 7,060 | 27.2K $ | 0.37 % | as of Jun 30, 2026 ↗ | |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 5,348 | 28.1K $ | 0.28 % | as of May 31, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 1,699 | 8.9K $ | 0.09 % | as of May 31, 2026 ↗ | |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 143 | 750.8 $ | 0.01 % | as of May 31, 2026 ↗ | |
| Diversified Equity Alpha Master Portfolio Master Investment Portfolio | 89 | 342.7 $ | 0.00 % | as of Jun 30, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 6 | 0 | 31,399 | +36.7 % |
| 2026Q2 | 6 | 0 | 22,975 | +8.0 % |
| 2026Q1 | 6 | -1 | 21,266 | -52.4 % |
| 2025Q4 | 7 | +2 | 44,644 | -24.9 % |
| 2025Q3 | 5 | 59,412 |
Institutional managers
21 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| Sofinnova Investments, Inc. | 137,721 | 556.4K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 77,225 | 312K $ | as of Mar 31, 2026 |
| Vivo Capital, LLC | 72,414 | 292.6K $ | as of Mar 31, 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC | 42,581 | 172K $ | as of Mar 31, 2026 |
| T3 Companies, LLC | 38,000 | 153.5K $ | as of Mar 31, 2026 |
| Board of Trustees of The Leland Stanford Junior University | 35,977 | 145.3K $ | as of Mar 31, 2026 |
| Pfizer Inc | 31,305 | 137.1K $ | as of Mar 31, 2026 |
| Lynx1 Capital Management LP | 30,800 | 124.4K $ | as of Mar 31, 2026 |
| Nan Fung Group Holdings Ltd | 29,250 | 118.2K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 28,791 | 116.3K $ | as of Mar 31, 2026 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 27,500 | 111.1K $ | as of Mar 31, 2026 |
| Shay Capital LLC | 14,905 | 60.2K $ | as of Mar 31, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 11,657 | 47.1K $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 10,109 | 40.8K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 9,711 | 39.2K $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 3,189 | 12.9K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 1,093 | 4.4K $ | as of Mar 31, 2026 |
| UBS Group AG | 787 | 3.2K $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 42 | 179 $ | as of Mar 31, 2026 |
| SBI Securities Co., Ltd. | 10 | 40 $ | as of Mar 31, 2026 |
| BARCLAYS PLC | 6 | 24 $ | as of Mar 31, 2026 |
Declared shareholders of BOLT BIOTHERAPEUTICS INC
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Renaissance Technologies LLC and 1 other | 5.13 % | 98,625 | as of Jun 24, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of BOLT BIOTHERAPEUTICS INC". https://titelia.com/en/stocks/bolt-biotherapeutics-inc-US0977022039